CGTLive®’s Weekly Rewind – March 1, 2024

News
Article

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

CGTLive®'s Weekly Rewind

CGTLive®'s Weekly Rewind

1. mHA-Specific Donor Tregs Show Potential in Preventing GvHD in Donor HCT

The expanded donor Treg clones maintained lineage fidelity and were persistent through 1 year post-HCT.

2. Paul Harmatz, MD, on Harnessing Accelerated Approval for LSDs, Rare Disease Treatment Advancements

The pediatric gastroenterologist and professor in residence at University of California at San Francisco discussed challenges in investigating therapies for rare diseases.

3. First Patient With Esophageal Cancer Receives TAC101-CLDN18.2 Cell Therapy

The patient is doing well so far and may receive a booster dose of the TAC cell therapy.

4. Paul Melmeyer, MPP, on Advocacy and Progress in Rare Neuromuscular Diseases From a Policy Standpoint

In observance of Rare Disease Day 2024, the vice president of public policy and advocacy at the Muscular Dystrophy Association discussed advocacy and policy progress regarding rare neuromuscular diseases.

5. Latest News in Cell and Gene Therapy for Rare Disease Day 2024

In observance of Rare Disease Day, held this year on February 29, catch up on some of the latest data updates from clinical trials for rare diseases.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine
Surbhi Sidana, MD, an assistant professor of medicine, bone marrow transplantation, and cellular therapy at Stanford
Damien Maura, PhD, a senior scientist at Voyager Therapeutics
© 2025 MJH Life Sciences

All rights reserved.